Taro Pharmaceutical Industries Ltd. (TARO)
- Previous Close
42.19 - Open
42.14 - Bid --
- Ask --
- Day's Range
42.14 - 42.19 - 52 Week Range
24.39 - 45.76 - Volume
2,573 - Avg. Volume
49,356 - Market Cap (intraday)
1.586B - Beta (5Y Monthly) 0.61
- PE Ratio (TTM)
34.58 - EPS (TTM)
1.22 - Earnings Date May 21, 2024 - May 27, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Dec 10, 2018
- 1y Target Est
43.00
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprising allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It distributes and sells its products directly to wholesalers, retail drug chains, food chains, hospitals, mass merchandisers, e-commerce stores, and other direct consumers, as well as healthcare institutions and private pharmacies. The company was incorporated in 1959 and is based in Haifa, Israel. Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Alkaloida Chemical Company Zrt. As of June 30, 2023, Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Sun Pharmaceutical Industries Limited.
www.taro.com1,554
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: TARO
Performance Overview: TARO
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TARO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TARO
Valuation Measures
Market Cap
1.59B
Enterprise Value
737.36M
Trailing P/E
34.58
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.60
Price/Book (mrq)
0.89
Enterprise Value/Revenue
1.21
Enterprise Value/EBITDA
9.53
Financial Highlights
Profitability and Income Statement
Profit Margin
7.48%
Return on Assets (ttm)
1.03%
Return on Equity (ttm)
2.61%
Revenue (ttm)
610.83M
Net Income Avi to Common (ttm)
45.7M
Diluted EPS (ttm)
1.22
Balance Sheet and Cash Flow
Total Cash (mrq)
902.22M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
81.01M
Research Analysis: TARO
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell